Search research articles
Contact Us
Filters
Showing results (51-60 of 307) with videos related to
Page
of 31
Sort By:
Seminars in Arthritis and Rheumatism
|
November 23, 2013
Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycans against synovial inflammation
Yves Henrotin, Cécile Lambert, Pascal Richette
Rheumatology (Oxford, England)
|
December 23, 2017
Cardiac and renal protective effects of urate-lowering therapy
Pascal Richette, Augustin Latourte, Thomas Bardin
Presse Medicale (Paris, France : 1983)
|
June 21, 2011
[New therapeutic options for gout]
Pascal Richette, Sébastien Ottaviani, Thomas Bardin
Arthritis Research & Therapy
|
September 6, 2011
Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy
Xavier Chevalier, Thierry Conrozier, Pascal Richette
Expert Opinion on Drug Metabolism & Toxicology
|
May 10, 2014
Pharmacokinetics considerations for gout treatments
Pascal Richette, Aline Frazier, Thomas Bardin
Joint Bone Spine
|
June 23, 2025
IL-6: A new target in crystal-induced arthritides - A narrative review
Augustin Latourte, Tristan Pascart, Pascal Richette
Joint Bone Spine
|
October 24, 2007
Achondroplasia: from genotype to phenotype
Pascal Richette, Thomas Bardin, Chantal Stheneur
Expert Opinion on Drug Safety
|
July 3, 2015
Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend?
Pascal Richette, Augustin Latourte, Aline Frazier
Current Opinion in Rheumatology
|
January 17, 2015
Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout
Pascal Richette, Aline Frazier, Thomas Bardin
Nature Reviews. Rheumatology
|
April 3, 2013
Biologic agents in osteoarthritis: hopes and disappointments
Xavier Chevalier, Florent Eymard, Pascal Richette
Page
of 31
Search research articles
Search
Showing results (51-60 of 307) with videos related to
Sort By:
Page
of 31
Seminars in Arthritis and Rheumatism
|
November 23, 2013
Importance of synovitis in osteoarthritis: evidence for the use of glycosaminoglycans against synovial inflammation
Yves Henrotin, Cécile Lambert, Pascal Richette
Rheumatology (Oxford, England)
|
December 23, 2017
Cardiac and renal protective effects of urate-lowering therapy
Pascal Richette, Augustin Latourte, Thomas Bardin
Presse Medicale (Paris, France : 1983)
|
June 21, 2011
[New therapeutic options for gout]
Pascal Richette, Sébastien Ottaviani, Thomas Bardin
Arthritis Research & Therapy
|
September 6, 2011
Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy
Xavier Chevalier, Thierry Conrozier, Pascal Richette
Expert Opinion on Drug Metabolism & Toxicology
|
May 10, 2014
Pharmacokinetics considerations for gout treatments
Pascal Richette, Aline Frazier, Thomas Bardin
Joint Bone Spine
|
June 23, 2025
IL-6: A new target in crystal-induced arthritides - A narrative review
Augustin Latourte, Tristan Pascart, Pascal Richette
Joint Bone Spine
|
October 24, 2007
Achondroplasia: from genotype to phenotype
Pascal Richette, Thomas Bardin, Chantal Stheneur
Expert Opinion on Drug Safety
|
July 3, 2015
Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend?
Pascal Richette, Augustin Latourte, Aline Frazier
Current Opinion in Rheumatology
|
January 17, 2015
Impact of anti-inflammatory therapies, xanthine oxidase inhibitors and other urate-lowering therapies on cardiovascular diseases in gout
Pascal Richette, Aline Frazier, Thomas Bardin
Nature Reviews. Rheumatology
|
April 3, 2013
Biologic agents in osteoarthritis: hopes and disappointments
Xavier Chevalier, Florent Eymard, Pascal Richette
Page
of 31